Navigation Links
Antibody signal may redirect inflammation to fuel cancer

As evidence mounts that the body's normally protective inflammation response can drive some precancerous tissues to become fully malignant, UCSF scientists report discovering an apparent trigger to this potentially deadly process.

Typically, the "innate" immune system's Pac-Man-like white blood cells, or leukocytes, engulf and destroy invading microbes when receptors on their surface receive a signal from serum in the blood -- often an antibody produced by a B cell in the separately evolved "acquired" immune system.

Now UCSF researchers have found that in the presence of precancerous tissue, leukocyte antibody receptors can also be activated to turn on a dangerously different program: inducing leukocytes to boost cell growth, increase the number of blood vessels and "remodel" tissue in the area -- all of which help cancer develop.

The finding adds a critical and surprising detail to the emerging view that inflammation, usually a helpful response to invading pathogens, can become misdirected and fuel cancer.

The new research was presented today (February 19) by UCSF scientist Lisa M. Coussens, PhD, at the annual meeting of the American Association for the Advancement of Science (AAAS) in a session titled "healthy aging: inflammation and chronic diseases."

"Immunologists have known for decades that B cells of the so-called adaptive or acquired immune system are activated following a bacterial infection and in response, produce antibodies that signal leukocytes to attack," said Coussens, associate professor of pathology in the UCSF Cancer Research Institute. "But in precancerous tissue in mice, we have found that leukocytes apparently receive signals to switch programs, stimulating cell growth and increasing blood supply -- processes that would normally help healing from an infection, but can instead fuel cancer cell development."

The researchers have not yet identified what specific signal or signals are inv olved, but preliminary evidence indicates that antibodies may signal specific receptors on leukocytes to enhance the cancer-promoting pathway. Part of the receptor for the antibody known as immunoglobulin appears to be involved, Coussens said.

The good news, she adds, is that potential drugs to block this pathway are already being tested in clinical trials to treat B cell lymphoma and auto-immune diseases made worse by inflammation, such as rheumatoid arthritis.

"We already know that inflammation accelerates skin, cervical and colon cancer, and most likely also lung and breast cancer," she said. "If we confirm that what we've discovered in the mice studies also occurs in human cancers, we may soon be in a good position to slow this cancer process using drugs already under study for severe immune disorders."

Coussens envisions a therapeutic strategy similar to treating people with HIV. The goal would not be to necessarily eliminate every last cancer cell, but to control the inflammation process needed for the cancer to progress to a more threatening stage.

The new UCSF finding comes from studies with mice genetically engineered to carry some of the genes of the human papilloma virus (HPV), a pathogen that is known to cause human cervical cancer. By comparing cancer progression in these mice compared with gene "knock-out mice" that lacked the antibody receptors normally active on the leukocyte surfaces, Coussens and her colleagues discovered that the receptors were involved for the cancer to progress rapidly.

The new discovery follows one by Coussens and colleagues two years ago, published in "Cancer Cell" (1) that determined that antibody-producing B cells are essential for the harmful redirection of the leukocyte response. The finding startled many in the field because the B cells do not act at the site of inflammation where the leukocytes are located, so they apparently send the crucial signals remotely through th e blood’s serum. The surprising nature of the discovery and its implications were explored in a June 2005 commentary in "Nature" (2).

A review this month by Coussens and Ting-Ting Tan, PhD, a postdoctoral fellow in Coussens?laboratory, brings together many related threads of research in this fast-evolving area of inquiry. It was published February 1 in "Current Opinion in Immunology" (3).

Coussens stresses that because of the unique antibody makeup of each person, there is no evidence and no likelihood that periodic booster shots of the immunoglobulin antibody, or even blood transfusions from someone with precancerous tissue could trigger cancer progression in a recipient.
'"/>

Source:University of California - San Francisco


Related biology news :

1. Antibody extends life of mice with breast cancer
2. Antibody therapy prevents type 1 diabetes in mice
3. Plants respond similarly to signals from friends, enemies
4. Bound for destruction: Ubiquitination protects against improper Notch signaling
5. Viral protein influences key cell-signaling pathway
6. Researchers find promising cancer-fighting power of synthetic cell-signaling molecule
7. Edible bivalves as a source of human pathogens: signals between vibrios and the bivalve host.
8. Scientists discover that three overlapping signals in embryo help get the backbone right
9. After a time-shift, mixed signals from the circadian clock
10. Researchers make surprise discovery that some neurons can transmit three signals at once
11. Structure-building cell signals also may influence learning and memory

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/20/2016)... LONDON , Jan. 20, 2016 A ... positioned to directly benefit from the explosion in genomics ... from Howe Sound Research. A range of dynamic trends ... ...... - personalized medicine - pharmacogenomics - pathogen ... economies with large markets - greater understanding of the ...
(Date:1/15/2016)... Jan. 15, 2016 Recent publicized breaches in ... find new ways to ensure data security and user ... and Android that ties a user,s ... it into a hardware authorization token. Customer service agents ... fingerprint on their KodeKey enabled device to verify their ...
(Date:1/11/2016)... Jan. 11, 2016  higi, the leading retail ... retail locations, web and mobile, today announced it ... from existing investors. --> ... to further innovate higi,s health platform – its ... portal – including expanding services and programs to ...
Breaking Biology News(10 mins):
(Date:2/11/2016)... Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results ... --> --> For the fourth quarter ... or $0.34 loss per share, compared to a net loss of ... in 2014. For the year ended December 31, 2015, the Company ... share, as compared to a net loss of $60.5 million, or ...
(Date:2/11/2016)... and GERMANTOWN, Maryland , ... Frankfurt Prime Standard: QIA) today announced the introduction of ... gene expression profiling, expanding QIAGEN,s portfolio of Sample to ... researchers to select from over 20,000 human genes and ... between genes, cellular phenotypes and disease processes. --> ...
(Date:2/11/2016)... Feb. 11, 2016  Spectra BioPharma Selling Solutions (Spectra) ... provides biopharma companies the experience, expertise, operational delivery ... outsourced sales teams. Created in concert with industry ... the strategic and tactical needs of its clients ... through both personal and non-personal promotion. ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... to delivering cutting-edge information focused on the development and manufacture of biopharmaceuticals ... a premier sponsor of the 2016 BioProcess International Awards – Recognizing Excellence ...
Breaking Biology Technology: